The potential cost-effectiveness of adding a human papillomavirus vaccine to the cervical cancer screening programme in South Africa
Authors:
- Edina SinanovicESEdina Sinanovic
- Jennifer MoodleyJMJennifer Moodley
- Mark A. BaroneMBMark A. Barone
- Sumaya MallSMSumaya Mall
- Susan ClearySCSusan Cleary
- Jane HarriesJHJane Harries
- 1 October 2009
- Vol. 27 (44) , 6196-6202
Abstract
No abstract availableKeywords
This publication has 19 references indexed in Scilit:
- Preparing for HPV vaccination in South Africa: Key challenges and opinionsVaccine, 2009
- Economic evaluation of human papillomavirus vaccination in the United KingdomBMJ, 2008
- Health and economic outcomes of HPV 16,18 vaccination in 72 GAVI-eligible countriesVaccine, 2008
- Cost-effectiveness of HPV 16, 18 vaccination in BrazilVaccine, 2007
- The potential cost-effectiveness of prophylactic human papillomavirus vaccines in CanadaVaccine, 2007
- Model for Assessing Human Papillomavirus Vaccination StrategiesEmerging Infectious Diseases, 2007
- Challenges in implementing a cervical screening program in South AfricaCancer Detection Prevention, 2006
- Cost-Effectiveness of Cervical-Cancer Screening in Five Developing CountriesNew England Journal of Medicine, 2005
- A Controlled Trial of a Human Papillomavirus Type 16 VaccineNew England Journal of Medicine, 2002
- The role of cost-effectiveness analysis in health and medicine. Panel on Cost-Effectiveness in Health and MedicineJAMA, 1996